Lupin receives FDA approval for arthritis drug

November 04, 2014 | Tuesday | News | By BioSpectrum Bureau

Lupin receives FDA approval for arthritis drug

The approval has been granted for celecoxib capsules in 50 mg strength

Lupin has announced that it has received approval from the United States Food and Drugs Administration (USFDA) to market generic version of GD Searle LLC's Celebrex capsules, used to treat arthritis.

The company has received final approval for its Celecoxib Capsules in 50 mg strength and also received tentative approvals for its product in strengths of 100 mg, 200 mg and 400 mg.

According to IMS sales data, Celebrex capsules had annual US sales of $2.44 billion.